NDAORALTABLET
Approved
Jan 2013
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
25
Mechanism of Action
agents: alogliptin and pioglitazone. Alogliptin Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals. These hormones cause…
Indications (2)
Clinical Trials (5)
Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus
Started Jul 2017
0Diabetes Mellitus, Type 2
Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"
Started Feb 2017
1,026 enrolled
Type 2 Diabetes Mellitus
Phase 3 Alogliptin Pediatric Study
Started Oct 2016
152 enrolled
Diabetes Mellitus, Type 2
An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2
Started Sep 2016
1,409 enrolled
Diabetes Mellitus
Phase 1 Bioavailability Study of SYR-322MET
Started Apr 2016
24 enrolled
Healthy Volunteers
Loss of Exclusivity
LOE Date
Jun 4, 2029
39 months away
Patent Expiry
Jun 4, 2029